CL2021000514A1 - Dimetilaminoazetidinaminas como inhibidores de jak - Google Patents

Dimetilaminoazetidinaminas como inhibidores de jak

Info

Publication number
CL2021000514A1
CL2021000514A1 CL2021000514A CL2021000514A CL2021000514A1 CL 2021000514 A1 CL2021000514 A1 CL 2021000514A1 CL 2021000514 A CL2021000514 A CL 2021000514A CL 2021000514 A CL2021000514 A CL 2021000514A CL 2021000514 A1 CL2021000514 A1 CL 2021000514A1
Authority
CL
Chile
Prior art keywords
dimethylaminoazetidinamines
compounds
jak inhibitors
provides
variables
Prior art date
Application number
CL2021000514A
Other languages
English (en)
Inventor
Cameron Smith
Daniel D Long
Corbin Thompson
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CL2021000514A1 publication Critical patent/CL2021000514A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona compuestos de la fórmula (I): donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable de estas, que son útiles como inhibidores de la cinasa JAK. La invención también proporciona composiciones farmacéuticas que comprenden dichos compuestos, y métodos de uso de dichos compuestos para tratar las enfermedades respiratorias.
CL2021000514A 2018-09-04 2021-03-02 Dimetilaminoazetidinaminas como inhibidores de jak CL2021000514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862726562P 2018-09-04 2018-09-04

Publications (1)

Publication Number Publication Date
CL2021000514A1 true CL2021000514A1 (es) 2021-07-23

Family

ID=67982186

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000514A CL2021000514A1 (es) 2018-09-04 2021-03-02 Dimetilaminoazetidinaminas como inhibidores de jak

Country Status (17)

Country Link
US (3) US10947229B2 (es)
EP (1) EP3837258B1 (es)
JP (2) JP7324836B2 (es)
KR (1) KR20210056381A (es)
CN (1) CN112739697B (es)
AR (1) AR116115A1 (es)
AU (1) AU2019336167A1 (es)
BR (1) BR112021004052A2 (es)
CL (1) CL2021000514A1 (es)
CO (1) CO2021002977A2 (es)
EA (1) EA202190681A1 (es)
IL (1) IL281146B2 (es)
MA (1) MA53229A (es)
MX (1) MX2021002521A (es)
SG (1) SG11202101734RA (es)
TW (1) TWI791886B (es)
WO (1) WO2020051105A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180073687A (ko) 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
TWI808250B (zh) 2018-09-04 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 用於製備jak抑制劑之方法及其中間體
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
KR20210056381A (ko) 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021226637A1 (en) * 2020-05-08 2021-11-11 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus with nezulcitinib
US20230021647A1 (en) * 2021-06-21 2023-01-26 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
EP4359402A1 (en) * 2021-06-25 2024-05-01 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
WO2023215478A1 (en) * 2022-05-05 2023-11-09 Theravance Biopharma R&D Ip, Llc Nezulcitinib for delivery by nebulized oral inhalation
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
PL3001903T3 (pl) 2009-12-21 2018-03-30 Samumed, Llc 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP3318565B1 (en) 2013-12-05 2021-04-14 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
TN2016000503A1 (en) 2014-05-14 2018-04-04 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
KR20180073687A (ko) * 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
WO2017077288A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
CA3037243A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1 h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US20180258546A1 (en) 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
EP3619208B1 (en) 2017-05-01 2023-06-07 Theravance Biopharma R&D IP, LLC Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
KR20210056381A (ko) * 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
TWI808250B (zh) 2018-09-04 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 用於製備jak抑制劑之方法及其中間體
JP2022506111A (ja) 2018-10-29 2022-01-17 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物
PE20212069A1 (es) 2019-02-25 2021-10-26 Henan Medinno Pharmaceutical Tech Co Ltd Compuesto inhibidor de jak y uso del mismo
US11406640B2 (en) 2019-03-05 2022-08-09 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021226637A1 (en) * 2020-05-08 2021-11-11 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus with nezulcitinib
US20230021647A1 (en) * 2021-06-21 2023-01-26 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l

Also Published As

Publication number Publication date
IL281146B1 (en) 2023-08-01
MX2021002521A (es) 2021-04-28
US11634419B2 (en) 2023-04-25
US20210155620A1 (en) 2021-05-27
SG11202101734RA (en) 2021-03-30
IL281146B2 (en) 2023-12-01
JP7324836B2 (ja) 2023-08-10
CN112739697A (zh) 2021-04-30
MA53229A (fr) 2022-05-11
CO2021002977A2 (es) 2021-05-31
EA202190681A1 (ru) 2021-05-28
BR112021004052A2 (pt) 2021-05-25
AU2019336167A1 (en) 2021-03-11
KR20210056381A (ko) 2021-05-18
WO2020051105A1 (en) 2020-03-12
CN112739697B (zh) 2023-10-20
JP2021535177A (ja) 2021-12-16
US20200071323A1 (en) 2020-03-05
EP3837258A1 (en) 2021-06-23
EP3837258B1 (en) 2024-04-24
TW202024073A (zh) 2020-07-01
JP2022172299A (ja) 2022-11-15
US20230322774A1 (en) 2023-10-12
IL281146A (en) 2021-04-29
US10947229B2 (en) 2021-03-16
TWI791886B (zh) 2023-02-11
AR116115A1 (es) 2021-03-31

Similar Documents

Publication Publication Date Title
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
CL2019002204A1 (es) Compuestos inhibidores del vih.
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
EA201990019A1 (ru) Соединения и композиции для подавления активности shp2
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
CL2019003049A1 (es) Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats.
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
EA201791576A1 (ru) Ингибитор jak
CL2020001090A1 (es) Compuesto de pirimidina como inhibidor de las janocinasas.
EA201792116A1 (ru) Ингибитор янус-киназы
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201892219A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.